

Mike P Wattjes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2058980/publications.pdf>

Version: 2024-02-01

113
papers

4,721
citations

126907

33
h-index

110387

64
g-index

116
all docs

116
docs citations

116
times ranked

6600
citing authors

#	ARTICLE	IF	CITATIONS
1	The potential role of diffusion weighted imaging in the diagnosis of early carotid and vertebral artery dissection. <i>Neuroradiology</i> , 2022, 64, 1135-1144.	2.2	2
2	Analysis of deep grey nuclei susceptibility in early childhood: a quantitative susceptibility mapping and R2* study at 3 Tesla. <i>Neuroradiology</i> , 2022, 64, 1021-1031.	2.2	3
3	The neuroradiology of progressive multifocal leukoencephalopathy: a clinical trial perspective. <i>Brain</i> , 2022, 145, 426-440.	7.6	13
4	Innovative therapeutic concepts of progressive multifocal leukoencephalopathy. <i>Journal of Neurology</i> , 2022, 269, 2403-2413.	3.6	12
5	Neurological management and work-up of neurotoxicity associated with CAR T cell therapy. <i>Neurological Research and Practice</i> , 2022, 4, 1.	2.0	9
6	The reality of multiple sclerosis assessment in middle-income countries – Authors' reply. <i>Lancet Neurology</i> , The, 2022, 21, 215-216.	10.2	0
7	Are Apathy and Depressive Symptoms Related to Vascular White Matter Hyperintensities in Severe Late Life Depression?. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2021, 34, 21-28.	2.3	12
8	Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	19
9	Pharmacovigilance during treatment of multiple sclerosis: early recognition of CNS complications. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 177-188.	1.9	9
10	The sequence of structural, functional and cognitive changes in multiple sclerosis. <i>NeuroImage: Clinical</i> , 2021, 29, 102550.	2.7	21
11	Manual and automated tissue segmentation confirm the impact of thalamus atrophy on cognition in multiple sclerosis: A multicenter study. <i>NeuroImage: Clinical</i> , 2021, 29, 102549.	2.7	20
12	Automated quantitative MRI volumetry reports support diagnostic interpretation in dementia: a multi-rater, clinical accuracy study. <i>European Radiology</i> , 2021, 31, 5312-5323.	4.5	19
13	Development and evaluation of a manual segmentation protocol for deep grey matter in multiple sclerosis: Towards accelerated semi-automated references. <i>NeuroImage: Clinical</i> , 2021, 30, 102659.	2.7	3
14	Severe allo-immune antibody-associated peripheral and central nervous system diseases after allogeneic hematopoietic stem cell transplantation. <i>Scientific Reports</i> , 2021, 11, 8527.	3.3	6
15	Varicella zoster-associated acute retinal necrosis and central nervous system complications in natalizumab treated MS patients. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 50, 102838.	2.0	9
16	Allogeneic BK Virus-Specific T-Cell Treatment in 2 Patients With Progressive Multifocal Leukoencephalopathy. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, e1020.	6.0	19
17	Autoantibody-associated psychiatric syndromes in children: link to adult psychiatry. <i>Journal of Neural Transmission</i> , 2021, 128, 735-747.	2.8	6
18	2021 MAGNIMS – CMSC – NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. <i>Lancet Neurology</i> , The, 2021, 20, 653-670.	10.2	302

#	ARTICLE	IF	CITATIONS
19	PD-1-inhibitor pembrolizumab for treatment of progressive multifocal leukoencephalopathy. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642199368.	3.5	9
20	Infratentorial and spinal cord lesions: Cumulative predictors of long-term disability?. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1381-1391.	3.0	22
21	Single-subject structural cortical networks in clinically isolated syndrome. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1392-1401.	3.0	10
22	Measurements of the corpus callosum index and fractional anisotropy of the corpus callosum and their cutoff values are useful to assess global brain volume loss in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 45, 102388.	2.0	13
23	Autoantibody-associated psychiatric symptoms and syndromes in adults: A narrative review and proposed diagnostic approach. <i>Brain, Behavior, & Immunity - Health</i> , 2020, 9, 100154.	2.5	41
24	Personalized extended interval dosing of natalizumab in MS. <i>Neurology</i> , 2020, 95, e745-e754.	1.1	36
25	A clinical-radiological framework of the right temporal variant of frontotemporal dementia. <i>Brain</i> , 2020, 143, 2831-2843.	7.6	76
26	Diagnosis and Differential Diagnosis of Neurological Adverse Events during Immune Checkpoint Inhibitor Therapy. <i>Journal of Oncology</i> , 2020, 2020, 1-9.	1.3	6
27	Quantitative Imaging in Muscle Diseases with Focus on Non-proton MRI and Other Advanced MRI Techniques. <i>Seminars in Musculoskeletal Radiology</i> , 2020, 24, 402-412.	0.7	4
28	Application of "Mentzer's PML case definition" to natalizumab-treated patients in the setting of strict MRI-based pharmacovigilance. <i>Journal of Neurology</i> , 2020, 267, 2599-2602.	3.6	3
29	Clinical, Radiological, and Laboratory Features of Spinal Cord Involvement in Primary Sjögren's Syndrome. <i>Journal of Clinical Medicine</i> , 2020, 9, 1482.	2.4	13
30	Mild COVID-19 symptoms despite treatment with teriflunomide and high-dose methylprednisolone due to multiple sclerosis relapse. <i>Journal of Neurology</i> , 2020, 267, 2803-2805.	3.6	20
31	Gadolinium should always be used to assess disease activity in MS "No. <i>Multiple Sclerosis Journal</i> , 2020, 26, 767-769.	3.0	9
32	Clinico-radiological dissociation of disease activity in MS patients: frequency and clinical relevance. <i>Journal of Neurology</i> , 2020, 267, 3287-3291.	3.6	2
33	SPG7 mutations in amyotrophic lateral sclerosis: a genetic link to hereditary spastic paraplegia. <i>Journal of Neurology</i> , 2020, 267, 2732-2743.	3.6	14
34	Performance of PML diagnostic criteria in natalizumab-associated PML: data from the Dutch-Belgian cohort. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 44-46.	1.9	18
35	Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines. <i>Brain</i> , 2019, 142, 1858-1875.	7.6	303
36	Serum neurofilaments as candidate biomarkers of natalizumab associated progressive multifocal leukoencephalopathy. <i>Annals of Neurology</i> , 2019, 86, 322-324.	5.3	11

#	ARTICLE	IF	CITATIONS
37	Personalized risk for clinical progression in cognitively normal subjects—the ABIDE project. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 33.	6.2	30
38	Towards a standard MRI protocol for multiple sclerosis across the UK. <i>British Journal of Radiology</i> , 2019, 92, 20180926.	2.2	9
39	Individual Prediction of Behavioral Variant Frontotemporal Dementia Development Using Multivariate Pattern Analysis of Magnetic Resonance Imaging Data. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 1229-1241.	2.6	14
40	Impact of the McDonald Criteria 2017 on Early Diagnosis of Relapsing-Remitting Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2019, 10, 188.	2.4	52
41	Imaging of meningeal inflammation should become part of the routine MRI protocol – No. <i>Multiple Sclerosis Journal</i> , 2019, 25, 331-333.	3.0	3
42	Exploring resting state connectivity in patients with psychotic depression. <i>PLoS ONE</i> , 2019, 14, e0209908.	2.5	10
43	Impact of 3 Tesla MRI on interobserver agreement in clinically isolated syndrome: A MAGNIMS multicentre study. <i>Multiple Sclerosis Journal</i> , 2019, 25, 352-360.	3.0	22
44	Gray matter networks and cognitive impairment in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 382-391.	3.0	39
45	Disease activity following pregnancy-related discontinuation of natalizumab in MS. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2018, 5, e424.	6.0	15
46	Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis. <i>JAMA Neurology</i> , 2018, 75, 827.	9.0	29
47	The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing. <i>Multiple Sclerosis Journal</i> , 2018, 24, 805-810.	3.0	32
48	The value of subtraction MRI in detection of amyloid-related imaging abnormalities with oedema or effusion in Alzheimer's™s patients: An interobserver study. <i>European Radiology</i> , 2018, 28, 1215-1226.	4.5	8
49	Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1453-1460.	3.0	18
50	Inflammatory natalizumab-associated PML: baseline characteristics, lesion evolution and relation with PML-IRIS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 535-541.	1.9	31
51	Venoplasty in MS. <i>Neurology</i> , 2018, 91, 815-816.	1.1	0
52	Imaging Patterns of Muscle Atrophy. <i>Seminars in Musculoskeletal Radiology</i> , 2018, 22, 299-306.	0.7	18
53	Gray matter atrophy in dementia with Lewy bodies with and without concomitant Alzheimer's disease pathology. <i>Neurobiology of Aging</i> , 2018, 71, 171-178.	3.1	25
54	Intracerebral lymphoproliferative disorder in an MS patient treated with fingolimod. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2018, 5, e483.	6.0	6

#	ARTICLE	IF	CITATIONS
55	Validation of an MRI Rating Scale for Amyloid-Related Imaging Abnormalities. <i>Journal of Neuroimaging</i> , 2017, 27, 318-325.	2.0	10
56	Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 6, 143-151.	2.4	57
57	Natalizumab-associated progressive multifocal leukoencephalopathy is not preceded by elevated drug concentrations. <i>Multiple Sclerosis Journal</i> , 2017, 23, 995-999.	3.0	9
58	In-vivo imaging of meningeal inflammation in multiple sclerosis: Presence of evidence or evidence of presence?. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1169-1171.	3.0	5
59	Application of the CSF JCV antibody index to early natalizumab-associated progressive multifocal leukoencephalopathy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 1092-1094.	1.9	17
60	Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases. <i>Journal of Neurology</i> , 2017, 264, 1155-1164.	3.6	77
61	Multiple sclerosis update: use of MRI for early diagnosis, disease monitoring and assessment of treatment related complications. <i>British Journal of Radiology</i> , 2017, 90, 20160721.	2.2	39
62	Brain and Spinal Cord MR Imaging Features in Multiple Sclerosis and Variants. <i>Neuroimaging Clinics of North America</i> , 2017, 27, 205-227.	1.0	25
63	Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer's Biomarkers in Daily Practice (ABIDE) Project. <i>JAMA Neurology</i> , 2017, 74, 1481.	9.0	77
64	Brain and Spinal Cord MRI in Multiple Sclerosis: an Update. <i>Neurology International Open</i> , 2017, 01, E294-E306.	0.4	3
65	Performance of five research-domain automated WM lesion segmentation methods in a multi-center MS study. <i>NeuroImage</i> , 2017, 163, 106-114.	4.2	27
66	Neuromyelitis optica spectrum disorder mimicking multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 17, 54-56.	2.0	2
67	[P1-400]: USING SUBTRACTION MRI TO IMPROVE THE DETECTION OF AMYLOID-RELATED IMAGING ABNORMALITIES WITH EDEMA OR EFFUSION (ARIA) IN PATIENTS AFFECTED BY ALZHEIMER'S DISEASE RECEIVING IMMUNOTHERAPY: AN INTER-OBSERVER STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P425.	0.8	0
68	[F1-03-04]: BIOMARKER-BASED PERSONALIZED RISK ESTIMATES FOR PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE. <i>Alzheimer's and Dementia</i> , 2017, 13, P177.	0.8	0
69	Acute influenza virus-associated encephalitis and encephalopathy in adults: a challenging diagnosis. <i>JMM Case Reports</i> , 2016, 3, e005076.	1.3	45
70	MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1138-1145.	1.9	59
71	Heterogeneous Language Profiles in Patients with Primary Progressive Aphasia due to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 581-590.	2.6	35
72	Recent developments in muscle imaging of neuromuscular disorders. <i>Current Opinion in Neurology</i> , 2016, 29, 614-620.	3.6	29

#	ARTICLE	IF	CITATIONS
73	Elevated CSF neurofilament proteins predict brain atrophy: A 15-year follow-up study. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1154-1162.	3.0	48
74	Multicenter Validation of Mean Upper Cervical Cord Area Measurements from Head 3D T1-Weighted MR Imaging in Patients with Multiple Sclerosis. <i>American Journal of Neuroradiology</i> , 2016, 37, 749-754.	2.4	30
75	Cerebral perfusion in the predementia stages of Alzheimer's disease. <i>European Radiology</i> , 2016, 26, 506-514.	4.5	99
76	Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1174-1183.	3.0	21
77	Concomitant granule cell neuronopathy in patients with natalizumab-associated PML. <i>Journal of Neurology</i> , 2016, 263, 649-656.	3.6	14
78	Whole brain functional connectivity in clinically isolated syndrome without conventional brain MRI lesions. <i>European Radiology</i> , 2016, 26, 2982-2991.	4.5	17
79	MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 879-884.	1.9	46
80	The identification of cognitive subtypes in Alzheimer's disease dementia using latent class analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 235-243.	1.9	89
81	Matrix Metalloproteinases in Alzheimer's Disease and Concurrent Cerebral Microbleeds. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 711-720.	2.6	71
82	Contribution of white matter hyperintensities, medial temporal lobe atrophy and cortical atrophy on outcome, seven to twelve years after ECT in severely depressed geriatric patients. <i>Journal of Affective Disorders</i> , 2015, 185, 144-148.	4.1	10
83	Unraveling the neuroimaging predictors for motor dysfunction in long-standing multiple sclerosis. <i>Neurology</i> , 2015, 85, 248-255.	1.1	41
84	Angiotensin-Converting Enzyme in Cerebrospinal Fluid and Risk of Brain Atrophy. <i>Journal of Alzheimer's Disease</i> , 2015, 44, 153-162.	2.6	18
85	Differential patterns of spinal cord and brain atrophy in NMO and MS. <i>Neurology</i> , 2015, 84, 1465-1472.	1.1	70
86	Left atrial myxoma presenting with white matter lesions suggestive of multiple sclerosis: The differential diagnosis goes beyond MRI. <i>Multiple Sclerosis Journal</i> , 2015, 21, 255-255.	3.0	1
87	Guidelines on PML risk stratification and diagnosis in patients with MS treated with natalizumab: so far so good?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 87, jnnp-2015-311386.	1.9	8
88	MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—establishing disease prognosis and monitoring patients. <i>Nature Reviews Neurology</i> , 2015, 11, 597-606.	10.1	422
89	Low JC virus antibody index during natalizumab treatment less safe than assumed?. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1753-1754.	3.0	2
90	Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1036-1044.	3.0	78

#	ARTICLE	IF	CITATIONS
91	MRI pattern in asymptomatic natalizumab-associated PML. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 793-798.	1.9	75
92	Progressive multifocal leukoencephalopathy after natalizumab discontinuation: Few and true?. Annals of Neurology, 2014, 75, 462-462.	5.3	16
93	Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI. Current Opinion in Neurology, 2014, 27, 260-270.	3.6	61
94	Associations Between Cerebral Small-Vessel Disease and Alzheimer Disease Pathology as Measured by Cerebrospinal Fluid Biomarkers. JAMA Neurology, 2014, 71, 855.	9.0	140
95	Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy. Annals of Neurology, 2014, 76, 792-801.	5.3	82
96	Determinants of iron accumulation in deep grey matter of multiple sclerosis patients. Multiple Sclerosis Journal, 2014, 20, 1692-1698.	3.0	47
97	White Matter Hyperintensities and Cognitive Impairment During Electroconvulsive Therapy in Severely Depressed Elderly Patients. American Journal of Geriatric Psychiatry, 2014, 22, 157-166.	1.2	25
98	Chronic cerebrospinal venous insufficiency in multiple sclerosis: the final curtain. Lancet, The, 2014, 383, 106-108.	13.7	14
99	The investigation of acute optic neuritis: a review and proposed protocol. Nature Reviews Neurology, 2014, 10, 447-458.	10.1	248
100	Diagnosis of asymptomatic natalizumab-associated PML: are we between a rock and a hard place?. Journal of Neurology, 2014, 261, 1139-1143.	3.6	30
101	Regional atrophy is associated with impairment in distinct cognitive domains in Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, S299-305.	0.8	31
102	The structure of the geriatric depressed brain and response to electroconvulsive therapy. Psychiatry Research - Neuroimaging, 2014, 222, 1-9.	1.8	25
103	O2-07-04: COGNITIVE SUBTYPES IN DEMENTIA DUE TO ALZHEIMER'S DISEASE IDENTIFIED BY LATENT CLASS ANALYSIS. , 2014, 10, P178-P179.		0
104	O5-05-04: MATRIX METALLOPROTEINASES IN RELATION TO ALZHEIMER'S DISEASE AND CAA. , 2014, 10, P300-P300.		0
105	Spinal cord lesions in patients with clinically isolated syndrome. Neurology, 2013, 80, 69-75.	1.1	140
106	The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy. Multiple Sclerosis Journal, 2013, 19, 1826-1840.	3.0	88
107	PS9 - 5. Proliferative retinopathy in type 1 diabetes is associated with cerebral microbleeds and decreased skin capillary density. Nederlands Tijdschrift Voor Diabetologie, 2013, 11, 169-169.	0.0	0
108	Diagnostic relevance of high field MRI in clinical neuroradiology: the advantages and challenges of driving a sports car. European Radiology, 2012, 22, 2304-2306.	4.5	5

#	ARTICLE	IF	CITATIONS
109	Structural MRI. <i>International Psychogeriatrics</i> , 2011, 23, S13-S24.	1.0	31
110	No association of abnormal cranial venous drainage with multiple sclerosis: a magnetic resonance venography and flow-quantification study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 429-435.	1.9	119
111	Neuromuscular imaging in inherited muscle diseases. <i>European Radiology</i> , 2010, 20, 2447-2460.	4.5	289
112	Diagnostic Imaging of Patients in a Memory Clinic: Comparison of MR Imaging and 64â€“Detector Row CT. <i>Radiology</i> , 2009, 253, 174-183.	7.3	121
113	High field MRI in the diagnosis of multiple sclerosis: high fieldâ€“high yield?. <i>Neuroradiology</i> , 2009, 51, 279-292.	2.2	75